BusinessConverGene Announces Sponsored Research Agreement with University of Maryland, Baltimore to Evaluate First-in-class Anti-cancer AgentsBy Nasdaq OMXJan 25, 2017, 3:18 PM UTC
BusinessKura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Chronic Myelomonocytic LeukemiaBy Nasdaq OMXJan 17, 2017, 12:30 PM UTC
BusinessAdvanced Accelerator Applications Announces New England Journal of Medicine Publication of Lutathera® NETTER-1 Phase III ResultsBy Nasdaq OMXJan 12, 2017, 1:05 PM UTC
BusinessKura Oncology Receives FDA Clearance to Proceed with Clinical Trial for ERK Inhibitor KO-947 and Nominates KO-539 as Development Candidate for Menin-MLL Inhibitor ProgramBy Nasdaq OMXJan 4, 2017, 12:30 PM UTC
BusinessConverGene Announces a License Agreement With the National Center for Advancing Translational SciencesBy Nasdaq OMXDec 13, 2016, 9:15 PM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2017 and Recent DevelopmentsBy Nasdaq OMXDec 12, 2016, 9:05 PM UTC
BusinessThe Fight Against Prostate Cancer: What Men Need to KnowBy Nasdaq OMXDec 8, 2016, 2:00 PM UTC
BusinessGalectin Therapeutics to Webcast Corporate Update At Annual Meeting of StockholdersBy Nasdaq OMXDec 8, 2016, 1:00 PM UTC
